Log In
BCIQ
Print this Print this
 

HylatopicPlus Emollient Foam

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionTopical ceramide-hyaluronic acid emollient foam
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacromolecule: Polysaccharide
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsTreat atopic dermatitis
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$500.0M

$475.0M

$25.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/08/2014

$500.0M

$475.0M

$25.0M

Get a free BioCentury trial today